"Designing Growth Strategies is in our DNA"

Non Small Cell Lung Cancer (NSCLC) Therapeutics Market Size, Share, Trends and Industry Analysis by Therapy (Targeted Therapy, Immunotherapy, Chemotherapy), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), By Cancer Type (Adenocarcinoma, Squamous cell carcinoma, Large cell carcinoma), and Regional Forecast 2025-2032

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI100484

 


To get information on various segments, share your queries with us

 SEGMENTATION

 DETAILS

By Therapy

·    Targeted Therapy

    ·   Bevacizumab

    ·    Dabrafenib/Trametinib

    ·   Erlotinib Hydrochloride

    ·   Osimertinib  

    ·   Others

·    Immunotherapy

    ·    Durvalumab

    ·    Nivolumab

    ·     Atezolizumab

    ·    Pembrolizumab

·    Chemotherapy

By Distribution Channel

·    Hospital Pharmacies

·    Retail Pharmacies

·    Online Pharmacies

·    Others

By Cancer Type

·    Adenocarcinoma

·    Squamous cell carcinoma

·    Large cell carcinoma

By Geography

·    North America (the U.S., and Canada)

·    Europe (Germany, U.K., France, Italy, Spain, Scandinavia, and Rest of Europe)

·    Asia Pacific (China, India, Japan, Australia, South East Asia, and Rest of Asia Pacific)

·    Latin America (Brazil, Mexico, and Rest of Latin America

·    Middle East & Africa (GCC, South Africa, and Rest of Middle East & Africa)

  • 2019-2032
  • 2024
  • 2019-2023
  • 160
Download Free Sample

    man icon
    Mail icon
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann